The human genome project and novel aspects of cytochrome P450 research

Toxicology and Applied Pharmacology

Volumn 207, Issue 2 SUPPL., 2005, Pages 52-56

  Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adverse drug reactions; CYP2R1; CYP2S1; CYP2U1; Genetic polymorphism; Naphtalene; Poor metabolizers; Ultrarapid metabolizers; Vitamin D

Indexed keywords

ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CARCINOGEN; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 2S1; CYTOCHROME P450 2U1; CYTOCHROME P450 2W1; CYTOCHROME P450 3A43; CYTOCHROME P450 CYP 2R1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NICOTINE; PROTON PUMP INHIBITOR; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SOLVENT; STEROID; UNCLASSIFIED DRUG; WARFARIN; XENOBIOTIC AGENT;

ALLELE; CONFERENCE PAPER; DNA POLYMORPHISM; DRUG METABOLISM; EVOLUTIONARY ADAPTATION; GENE CONTROL; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC DRIFT; GENOTYPE; HUMAN; HUMAN GENOME; PSEUDOGENE;

EID: 24644445302     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.01.030     Document Type: Conference Paper

References (22)

1. E. Aklillu, K. Herrlin, L.L. Gustafsson, L. Bertilsson, and M. Ingelman-Sundberg Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden Pharmacogenetics 12 2002 375 383
2. M. Amichot, S. Tarès, A. Brun-Barale, L. Arthaud, J.-M. Bride, and J.-P. Bergé Point mutations associated with insecticide resistance in the Drosophila cytochrome P450 Cyp6a2 enable DDT metabolism Eur. J. Biochem. 271 2004 1250 1257
3. J.B. Cheng, D.L. Motola, D.J. Mangelsdorf, and D.W. Russell De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxylase J. Biol. Chem. 278 2003 38084 38093
4. S.S. Chuang, C. Helvig, M. Taimi, H.A. Ramshaw, A.H. Collop, M. Amad, J.A. White, M. Petkovich, G. Jones, and B. Korczak CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes omega- and (omega-1)- hydroxylation of fatty acids J. Biol. Chem. 279 2004 6305 6314
5. P.J. Daborn, J.L. Yen, M.R. Bogwitz, G. Le Goff, E. Feil, S. Jeffers, N. Tijet, T. Perry, D. Heckel, P. Batterham, R. Feyereisen, T.G. Wilson, and R.H. French-Constant A single P450 allele associated with insecticide resistance in Drosophila Science 297 2002 2253 2256
6. T.L. Domanski, C. Finta, J.R. Halpert, and P.G. Zaphiropoulos cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450 Mol. Pharmacol. 59 2001 386 392
7. W.E. Evans, and M.V. Relling Moving towards individualized medicine with pharmacogenomics Nature 429 2004 464 468
8. M. Ingelman-Sundberg Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy J. Intern. Med. 250 2001 186 200
9. M. Ingelman-Sundberg Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future Trends Pharmacol. Sci. 25 2004 193 200
10. M. Ingelman-Sundberg Genetic polymorphisms of cytochrome P450 2DC (CYP2D6): clinical consequences, evolutionary aspects and functional diversity Pharmacogenomics J. 5 2005 6 13
11. M. Ingelman-Sundberg, M. Oscarson, and R.A. McLellan Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment Trends Pharmacol. Sci. 20 1999 342 349
12. M. Karlgren, M. Backlund, I. Johansson, M. Oscarson, and M. Ingelman-Sundberg Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1 Biochem. Biophys. Res. Commun. 315 2004 679 685
13. M. Karlgren, S.-I. Miura, and M. Ingelman-Sundberg Novel extrahepatic cytochrome P450s Toxicol. Appl. Pharmacol. 207 2005 57 61
14. C. Kawanishi, S. Lundgren, H. Agren, and L. Bertilsson Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study Eur. J. Clin. Pharmacol. 59 2004 803 807
15. J. Kirchheiner, K. Nickchen, M. Bauer, M.L. Wong, J. Licinio, I. Roots, and J. Brockmoller Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response Mol. Psychiatry 9 2004 442 473
16. D.R. Nelson, D.C. Zeldin, S.M. Hoffman, L.J. Maltais, W.H. Wain, and D.W. Nebert Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants Pharmacogenetics 14 2004 1 18
17. K.A. Phillips, D.L. Veenstra, E. Oren, J.K. Lee, and W. Sadee Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review JAMA 286 2001 2270 2279
18. T. Rau, G. Wohlleben, H. Wuttke, N. Thuerauf, J. Lunkenheimer, M. Lanczik, and T. Eschenhagen CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-A pilot study Clin. Pharmacol. Ther. 75 2004 386 393
19. S.P. Rivera, S.T. Saarikoski, and O. Hankinson Identification of a novel dioxin-inducible cytochrome P450 Mol. Pharmacol. 61 2002 255 259
20. T. Rylander, E.P. Neve, M. Ingelman-Sundberg, and M. Oscarson Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1) Biochem. Biophys. Res. Commun. 281 2001 529 535
21. G. Smith, C.R. Wolf, Y.Y. Deeni, R.S. Dawe, A.T. Evans, M.M. Comrie, J. Ferguson, and S.H. Ibbotson Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases Lancet 361 2003 1336 1343
22. A. Westlind, S. Malmebo, I. Johansson, C. Otter, T.B. Andersson, M. Ingelman-Sundberg, and M. Oscarson Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43 Biochem. Biophys. Res. Commun. 281 2001 1349 1355